



HbA_{1c}, Insulin Resistance, and β -Cell Function in Relation to Cognitive Function in Type 2 Diabetes: The CAROLINA Cognition Substudy

Diabetes Care 2019;42:e1–e3 | <https://doi.org/10.2337/dc18-0914>

Jolien Janssen,^{1,2}
 Esther van den Berg,^{1,3}
 Bernard Zinman,⁴ Mark A. Espeland,⁵
 Stefan L.C. Geijselaers,^{1,6}
 Michaela Mattheus,⁷
 Odd Erik Johansen,⁸ and
 Geert Jan Biessels¹

Cognitive dysfunction is increasingly recognized as a complication of type 2 diabetes. There is a growing evidence for etiologic roles of glycemia and insulin resistance, although important questions remain (1,2). Elevated levels of glycosylated hemoglobin (HbA_{1c}) appear to be related to worse cognition, but there are indications that the same holds true for lower HbA_{1c} levels, possibly because intensive glycemic control increases the risk of hypoglycemia (1). Previous studies relating HbA_{1c} to cognition did not sufficiently address this possible nonlinear relationship. Regarding insulin resistance, it has been postulated that disturbances in cerebral insulin signaling might negatively affect cognition (2). Indeed, in individuals without type 2 diabetes, both hyperinsulinemia and insulin resistance have been related to poorer cognitive performance and dementia (2). However, a comprehensive understanding of the interrelationship between markers of insulin homeostasis and cognition in type 2 diabetes is still lacking (1). Finally, there may be

interindividual differences in susceptibility for developing cognitive dysfunction, where factors such as age and sex could modify the relations between glycemia, insulin resistance, and cognition. We therefore investigated, in a large cohort of patients with type 2 diabetes, how HbA_{1c} and indices of insulin resistance and β -cell function relate to cognitive function, specifically addressing potential nonlinear associations and the influence of age and sex.

We studied participants of the cognition substudy of the CAROLINA (CARDiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes) trial (NCT01243424). CAROLINA is a randomized, active comparator, double-blind study of 6,041 patients with relatively early type 2 diabetes, where the primary purpose is to evaluate the cardiovascular safety and efficacy of the dipeptidyl peptidase 4 inhibitor linagliptin versus the sulfonylurea glimepiride. The CAROLINA cognition substudy investigates whether linagliptin is superior to glimepiride in the prevention of accelerated

cognitive decline (3). In brief, the Mini-Mental State Examination (MMSE), a test of global cognitive function, and the Trail Making Test and Verbal Fluency Test combined into one composite score for an attention and executive functioning score were conducted at baseline, after 160 weeks of treatment, and at study end (3). Baseline scores were used for the present analyses. Insulin resistance was assessed with the HOMA2 of insulin resistance (HOMA2-IR). Indices of β -cell function were proinsulin, C-peptide, the proinsulin-to-C-peptide ratio, and the HOMA2 of β -cell function (HOMA2- β). The relationships between HbA_{1c} and indices of insulin resistance and β -cell function and the cognitive measures, adjusted for confounders (age, sex, education, and race, and for HbA_{1c}, use of glinide or sulfonylurea), were assessed with ANCOVA; we also examined analyses stratified by HbA_{1c} (by median value), age (≥ 70 years, < 70 years), and sex (women, men). Nonlinear associations were addressed by adding a quadratic term of the mean-centered

¹Department of Neurology, Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht, the Netherlands

²Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, the Netherlands

³Department of Neurology, Erasmus MC University Medical Center, Rotterdam, the Netherlands

⁴Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, and Division of Endocrinology, University of Toronto, Toronto, Canada

⁵Department of Biostatistics and Data Science, Wake Forest School of Medicine, Winston-Salem, NC

⁶Department of Internal Medicine and Cardiovascular Research Institute, Maastricht University Medical Center+, Maastricht, the Netherlands

⁷Global Biometrics and Data Management, Boehringer Ingelheim, Ingelheim, Germany

⁸Clinical Development, Therapeutic Area CardioMetabolic, Boehringer Ingelheim, Asker, Norway

Corresponding author: Jolien Janssen, j.janssen-9@umcutrecht.nl

Received 26 April 2018 and accepted 8 October 2018

Clinical trial reg. no. NCT01243424, clinicaltrials.gov

© 2018 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at <http://www.diabetesjournals.org/content/license>.

Table 1—β-Coefficients (95% CIs) for the relationship between HbA_{1c} and indices of insulin resistance and β-cell function and MMSE

	N	Age (years) [†]		Sex [‡]		P for interaction	P for interaction
		<70	≥70	Men	Women		
HbA _{1c} (%)	4,335	-0.02 (-0.14, 0.10)	0.00 (-0.13, 0.14)	-0.05 (-0.30, 0.19)	0.02 (-0.12, 0.17)	-0.07 (-0.28, 0.15)	0.31
Median split							
<7.1%	2,148	0.50 (0.09, 0.90)*	1.06 (0.29, 1.83)*	0.06	0.36 (-0.12, 0.83)	0.65 (-0.06, 1.37)	0.36
≥7.1%	2,187	-0.27 (-0.49, -0.04)*	-0.70 (-1.15, -0.25)*	0.01*	-0.11 (-0.37, 0.15)	-0.51 (-0.91, -0.11)*	0.04*
Only patients without use of sulfonylurea or glinide							
β-Cell function							
C-peptide (nmol/L)	2,027	0.06 (-0.20, 0.32)	0.05 (-0.25, 0.35)	0.01 (-0.51, 0.53)	-0.08 (-0.36, 0.21)	0.39 (-0.16, 0.93)	0.19
Proinsulin (pmol/L)	2,232	-0.003 (-0.006, -0.001)*	-0.002 (-0.005, 0.001)	-0.007 (-0.015, 0.001)	-0.002 (-0.005, 0.001)	-0.006 (-0.012, 0.001)	0.31
Proinsulin-to-C-peptide ratio	2,011	-0.051 (-0.082, -0.021)*	-0.045 (-0.077, -0.012)*	-0.054 (-0.126, 0.018)	-0.021 (-0.053, 0.012)	-0.114 (-0.176, -0.052)*	0.01*
HOMA2-β	2,026	0.0006 (-0.0037, 0.0024)	-0.0010 (-0.0043, 0.0024)	-0.0008 (-0.0074, 0.0057)	-0.0011 (-0.0044, 0.0021)	0.0004 (-0.0058, 0.0067)	0.54
Insulin resistance							
HOMA2-IR	2,026	0.0119 (-0.0859, 0.1096)	0.0101 (-0.1011, 0.1212)	-0.0085 (-0.2085, 0.1915)	-0.0407 (-0.1444, 0.0630)	0.1432 (-0.0626, 0.3491)	0.18

Estimates for all patients are obtained from an ANCOVA with factors of sex and race (for HbA_{1c}, also use of sulfonylurea or glinide) and covariates of age, years of formal education, and baseline value of interest. Estimates within subgroup HbA_{1c} (<7.1%, ≥7.1%) are obtained from an ANCOVA using the same model within the HbA_{1c} subgroup. **P* < 0.05. †For the subgroup age (<70, ≥70 years), the same models without covariate age were run. ‡For the subgroup sex, the same models without factor sex were run. Interaction *P* values are taken from models as above with the additional subgroup term (subgroup age or sex, respectively) and interaction term (subgroup age × baseline value of interest or sex × baseline value of interest, respectively).

variable to the ANCOVA model. Potential confounding and mediating factors were added stepwise to the model to investigate any relationship further. Relationships between indices of insulin resistance and β-cell function and the cognitive measures were only examined in patients not using sulfonylurea or glinide.

This analysis involves 4,335 patients with type 2 diabetes (60.7% male; mean [SD] age 64.7 [9.4] years, diabetes duration 7.8 [6.2] years, HbA_{1c} 7.1 [0.6]% [55 (6) mmol/mol], MMSE score 28.0 [2.5]). The association between HbA_{1c} and MMSE was nonlinear (*P* < 0.001) and proved to be bell shaped. An analysis by median split (HbA_{1c} <7.1, ≥7.1% [*<*54, ≥54 mmol/mol]) revealed that both low and high HbA_{1c} levels were associated with worse performance (Table 1), independent of use of sulfonylurea or glinide, estimated glomerular filtration rate, duration of diabetes, depression, cardiovascular risk factors, macrovascular disease, microvascular complications, and diabetic foot. A significant age–HbA_{1c} interaction (*P* = 0.01) was observed, where data suggested that associations between both high and low HbA_{1c} levels and worse MMSE scores were most prominent in patients ≥70 years. A significant sex–HbA_{1c} interaction (*P* = 0.04) was also found in patients with HbA_{1c} levels ≥7.1% (54 mmol/mol), where data suggested a more prominent relationship between high HbA_{1c} and poor performance in women (Table 1). Negative linear associations were found between both proinsulin and the proinsulin-to-C-peptide ratio and the MMSE, independent of HbA_{1c}, HOMA2-IR, estimated glomerular filtration rate, duration of diabetes, depression, cardiovascular risk factors, macrovascular disease, microvascular complications, and diabetic foot. For the proinsulin-to-C-peptide ratio, a significant interaction with sex (*P* = 0.01) was observed. For other insulin-related measures (Table 1) and for the attention and executive functioning score (data on file), no significant (linear or nonlinear) associations were observed.

This large cross-sectional study in patients with type 2 diabetes shows a bell-shaped association between HbA_{1c} and cognitive function, with modifying effects of age and sex, with those over the age of 70 years and women being

more vulnerable. Although a causal relationship between HbA_{1c} and cognitive function cannot be inferred by these cross-sectional observations, they add to an emerging literature indicating that in older individuals, particularly, both tight and loose glycemic control may adversely affect cognition (1). This issue clearly needs further investigation. The lack of association between cognitive performance and C-peptide and the HOMA2 indices are congruent with recent studies in patients with type 2 diabetes (4). The negative linear association between elevated proinsulin and cognitive function could involve a direct effect of proinsulin on cardiovascular risk (5). Another explanation for this finding could be that proinsulin and the proinsulin-to-C-peptide ratio are more suitable markers of β -cell function in people with type 2 diabetes, particularly because proinsulin secreted by the β -cells increases further as diabetes progresses, whereas C-peptide and

insulin levels decrease when β -cells get exhausted.

Acknowledgments. The authors thank Elke Schüler, of Boehringer Ingelheim, for support in validating our database.

Duality of Interest. The CAROLINA cognition substudy is funded by the Boehringer Ingelheim and Eli Lilly and Company Diabetes Alliance. B.Z. and M.A.E. have served on scientific advisory boards and received honoraria or consulting fees from Boehringer Ingelheim. M.M. is the responsible trial statistician at Boehringer Ingelheim International GmbH. O.E.J. is clinical program leader at Boehringer Ingelheim International GmbH. The University Medical Center Utrecht receives financial support from Boehringer Ingelheim International GmbH for the work of G.J.B. on the CAROLINA cognition substudy. No other potential conflicts of interest relevant to this article were reported.

Author Contributions. J.J. performed the analyses and prepared the first draft and subsequent versions. E.v.d.B., O.E.J., and G.J.B. developed the research protocol. J.J., E.v.d.B., and G.J.B. developed the statistical analysis plan with input from M.M. M.M. checked all analyses performed by J.J. All authors read and approved

the final manuscript. J.J. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

References

1. Geijselaers SLC, Sep SJS, Stehouwer CDA, Biessels GJ. Glucose regulation, cognition, and brain MRI in type 2 diabetes: a systematic review. *Lancet Diabetes Endocrinol* 2015;3:75–89
2. Arnold SE, Arvanitakis Z, Macaulay-Rambach SL, et al. Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums. *Nat Rev Neurol* 2018;14:168–181
3. Biessels GJ, Janssen J, van den Berg E, et al.; CAROLINA Investigators. Rationale and design of the CAROLINA® - cognition substudy: a randomised controlled trial on cognitive outcomes of linagliptin versus glimepiride in patients with type 2 diabetes mellitus. *BMC Neurol* 2018;18:7
4. Geijselaers SLC, Sep SJS, Schram MT, et al. Insulin resistance and cognitive performance in type 2 diabetes - The Maastricht Study. *J Diabetes Complications* 2017;31:824–830
5. Zethelius B, Byberg L, Hales CN, Lithell H, Berne C. Proinsulin is an independent predictor of coronary heart disease: report from a 27-year follow-up study. *Circulation* 2002;105:2153–2158